News & AnalysisMetagenomi grabs $65m Series AMetagenomi, a next-generation gene editing company, has secured $65 million in Series A financing.ByIris Dorbian12 November 2020•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs